Department of Molecular Genetics, Kumamoto University School of Medicine, Kumamoto 862-0976, Japan
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Excess nitric oxide (NO) induces apoptosis
of some cell types, including macrophages. As NO is
synthesized by NO synthase (NOS) from arginine, a
common substrate of arginase, these two enzymes compete for arginine. There are two known isoforms of arginase, types I and II. Using murine macrophage-like
RAW 264.7 cells, we asked if the induction of arginase
II would downregulate NO production and hence
prevent apoptosis. When cells were exposed to lipopolysaccharide (LPS) and interferon- (IFN-
), the
inducible form of NOS (iNOS) was induced, production of NO was elevated, and apoptosis followed. When
dexamethasone and cAMP were further added, both
iNOS and arginase II were induced, NO production
was much decreased, and apoptosis was prevented.
When the cells were transfected with an arginase II expression plasmid and treated with LPS/IFN-
, some
cells were rescued from apoptosis. An arginase I expression plasmid was also effective. On the other hand,
transfection with the arginase II plasmid did not prevent apoptosis when a NO donor SNAP or a high concentration (12 mM) of arginine was added. These results indicate that arginase II prevents NO-dependent apoptosis of RAW 264.7 cells by depleting intracellular
arginine and by decreasing NO production.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
NITRIC oxide (NO)1 is an important multifunctional
biomolecule involved in a variety of physiological
and pathological processes, including regulation
of blood vessel dilatation and immune response, and functions as a neurotransmitter (Christopherson and Bredt, 1997; Harrison, 1997
; Mayer and Hemmens, 1997
; Nathan,
1997
). In pathologic processes, NO functions as a bactericidal or tumoricidal agent; however, excess NO production is thought to be the cause of several diseases, such as
septic shock (Stuehr and Marletta, 1985
), autoimmune disease (Farrell et al., 1992
), cerebral infarction (Dawson et al.,
1996
), and diabetes mellitus (Corbett and McDaniel, 1992
).
NO-mediated apoptosis is often observed in such cases
(Kröncke et al., 1997
). NO has several cytotoxic effects, including reactions with proteins and nucleic acids. The
main targets of NO in proteins are the SH group (Molina y
Vedia et al., 1992
) and Fe of active sites (Hibbs et al., 1988
),
especially Fe2+ (Kim et al., 1995
) in heme. In the nucleus,
NO has been shown to cause mutations of genes (Routledge et al., 1994
; Juedes and Wogan, 1996
), and inhibition
of DNA repair enzymes (Kwon et al., 1991
; Lepoivre et
al., 1991
), and to mediate DNA strand breaks (Nguyen et
al., 1992
; Fehsel et al., 1993
). In several types of cells including macrophages (Albina et al., 1993
; Sarih et al., 1993
), chondrocytes (Blanco et al., 1995
), neurons (Bonfoco et al., 1995
), and islet
cells (Kaneto et al., 1995
), NO
has been shown to mediate apoptosis (Dimmeler and
Zeiher, 1997
).
Morphologically, chromatin condensation, nuclear fragmentation, and formation of apoptotic body are characteristic changes of apoptosis (Kerr, 1995). In the cascade of
inducing these morphological changes, IL-1
-converting
enzyme (ICE)-like proteases or caspases play a key role
(Miura et al., 1993
; Nicholson et al., 1995
). Activation of
caspases leads to activation of a specific endonuclease (Enari et al., 1998
). Digestion of DNA at the linker portions of nucleosomes by endonuclease causes fragmentation of DNA (Gaido and Cidlowski, 1991
; Peitsch et al.,
1993
; Shiokawa et al., 1994
). Many agents including NO
synthase (NOS)-inducing agents have been shown to induce activation of caspases, and apoptosis follows (Hale
et al., 1996
).
NO is synthesized from arginine by NOS, generating citrulline. The availability of arginine is one of the rate limiting factors of cellular NO production. When the inducible
type NOS (iNOS) is induced, the activity is so high that the
supply of arginine is important. This amino acid can be obtained from blood circulation, intracellular protein degradation, or by regeneration from citrulline through the "citrulline-NO cycle" (Hecker et al., 1990; Hattori et al., 1994
;
Nussler et al., 1994
; Nagasaki et al., 1996
). As arginine is a
common substrate for NOS and arginase, arginase may
compete with NOS for arginine, and downregulate production of NO. Arginase exists in two known isoforms.
Liver-type arginase (arginase I) is expressed almost exclusively in the liver and catalyzes the last step of urea synthesis. However, we found that arginase I is highly induced in
rat macrophages activated with bacterial lipopolysaccharide (LPS; Sonoki et al., 1997
). On the other hand, nonhepatic type (arginase II) is expressed in some extrahepatic
tissues (Grody et al., 1989
). Recently, we (Gotoh et al.,
1996
) and others (Vockley et al., 1996
; Morris et al., 1997
)
cloned human arginase II cDNA and localized the arginase II gene to chromosome 14q24.1-24.3 (Gotoh et al.,
1997
). Activity (Wang et al., 1995
) and mRNA (Gotoh
et al., 1996
) of arginase II, as well as those of iNOS, are induced by LPS in murine macrophage-like RAW 264.7 cells. On the other hand, treatment of RAW cells with LPS and interferon-
(IFN-
) induces apoptosis (Messmer
et al., 1996
).
Here, we report that the LPS/IFN--dependent apoptosis of RAW cells is prevented by dexamethasone (Dex)
and cAMP, and that this antiapoptotic effect depends on
induction of arginase II that leads to suppression of iNOS-dependent production of NO in these cells.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasmids
pCAGGS-rAI, a mammalian expression plasmid for rat arginase I, was
constructed by inserting the EcoRI-PstI fragment of pARGr-2 (Kawamoto et al., 1987) into the EcoRI site of the plasmid pCAGGS (Niwa et al.,
1991
) after linker attachment. The rat arginase II cDNA clone was isolated by PCR, using mRNA from the small intestine of a male Wistar rat.
PCR was carried out using rat arginase II primers corresponding to nucleotides 86-1211 (GenBank, accession number U90887). The obtained
product was inserted into the HincII site of pGEM-3Zf(+) (), yielding pGEM-rAII-2.
Materials
Antiserum against human arginase II was raised in a rabbit by injecting Escherichia coli-expressed and the purified mature portion of human arginase II (residues 25-354). A monoclonal antibody against mouse iNOS was obtained from Transduction Laboratories.
Cell Culture and DNA Transfection
Mouse macrophage-like RAW 264.7 cells were grown in Eagle's minimal essential medium supplemented with 10% fetal calf serum. Transfection of RAW cells with plasmids was carried out using TransIT-LT1 Polyamine (PanVera Corp.) according to the protocol provided by the manufacturer.
Treatment of RAW Cells
RAW cells were cultured in medium with or without 1 µM Dex and/or 1 mM
dibutyryl cAMP for 24 h, and then treated with various combinations of E. coli LPS (serotype 0127:B8, , 150 µg/ml) and mouse
IFN- (100 U/ml) for indicated periods. A NO scavenger carboxy-PTIO
[2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide, 300 µM] or a NO donor SNAP (S-nitroso-N-acetyl-DL-penicillamine, 1 mM)
was added to the medium concomitantly with the addition of LPS and/or
IFN-
.
RNA Blot Analysis
Total RNA from RAW cells was prepared by the guanidium thiocyanate-phenol-chloroform extraction procedure (Chomczynski and Sacchi, 1987).
After electrophoresis in formaldehyde-containing agarose gels, RNAs
were transferred to nylon membranes. Hybridization was performed using
digoxigenin-labeled antisense RNAs as probes for rat iNOS, or rat arginase II. The antisense RNAs were synthesized using as templates
pcDNAII-riNOS (Nagasaki et al., 1996
), or pGEM-rAII-2, digested by
appropriate restriction enzymes. Chemiluminescence signals derived from
hybridized probes were detected on x-ray films using DIG luminescence
detection kits (), and were quantified using
a MacBAS bio-image analyzer (Fuji Photo Film Co.).
Immunoblot Analysis
RAW cells were homogenized in 20 mM Hepes-KOH (pH 7.5) containing 1% Triton X-100, 20% glycerol, and 1 mM dithiothreitol. After centrifugation, the supernatants were used as cell extracts for immunoblot analysis. The cell extracts were subjected to SDS-polyacrylamide gel electrophoresis, and proteins were electrotransferred to nitrocellulose membranes. Immunodetection was performed using ECL kits (Nycomed ), according to the protocol provided by the manufacturer. The results were quantified using a MacBAS bio-image analyzer.
Immunocytochemical Staining
RAW cells were cultured on coverslips and transfected with the human arginase II expression plasmid or stimulated with LPS (150 µg/ml), Dex (1 µM), and dibutyryl cAMP (1 mM), as described above. The cells were fixed with 4% paraformaldehyde for 40 min at room temperature and treated with phosphate-buffered saline containing 1% Triton X-100. The cells were then incubated with antiserum against human arginase II and then with goat anti-rabbit IgG conjugated with FITC (Vector Laboratories) as the second antibody. The stained cells were observed under a fluorescence microscope.
Detection of Apoptosis
RAW cells were treated as described above. To analyze morphological changes of nuclei, the cells were fixed, stained with 8 µg/ml of the Hoechst dye 33258 for 5 min, and washed with phosphate-buffered saline. The stained cells were observed under a fluorescence microscope. DNA fragmentation was detected by the terminal transferase-mediated dUTP-biotin nick end labeling method (TUNEL method), using in situ apoptosis detection kits (Takara) according to the protocol provided by the manufacturer. To detect DNA ladder formation, we used apoptosis ladder detection kits (Wako Pure Chemical Industries) according to the protocol provided by the manufacturer. DNA was isolated from the cells, resolved on agarose gels, stained with SYBR Green I, and visualized by UV transillumination.
Other Methods
Arginase activity was measured as described in Schimke (1962). Concentration of NO2
plus NO3
in culture supernatants was measured using
the Griess reagent with the NO2/NO3 assay kit-C (Dojindo Labs) after reduction of NO3
to NO2
according to the protocol provided by the manufacturer.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
LPS/IFN- Induces NO-mediated Apoptosis of
RAW Cells
When mouse macrophage-like RAW 264.7 cells were
treated with LPS/IFN- for 24 h, morphological changes
characteristic of apoptosis occurred (Fig. 1 A). Round-shaped cells and apoptotic bodies were observed in phase-contrast images, and chromatin condensation and nucleus
fragmentation were seen in the case of Hoechst dye 33258 staining. Most cells were positive for TUNEL staining.
These apoptotic changes were strongly prevented by adding a NO scavenger carboxy-PTIO (Akaike et al., 1993
;
Fig. 1 B). These results show that LPS/IFN-
induces apoptosis of RAW cells, and this apoptosis is mediated by NO.
LPS alone was much less effective in inducing apoptosis
(data not shown).
|
Induction of Arginase II Prevents iNOS-dependent Apoptosis of RAW Cells
NO is synthesized from arginine, a common substrate for
NOS and arginase. We reported that iNOS and arginase II
mRNAs are coinduced in RAW cells by LPS (Gotoh et al.,
1996). On the other hand, when these cells were treated
with LPS plus IFN-
, the induction of iNOS mRNA was
augmented, whereas the induction of arginase II was
strongly suppressed (Gotoh et al., 1996
).
We then asked whether LPS/IFN--induced apoptosis
would be prevented by arginase II induction. RAW cells
were cultured in the presence or absence of Dex/cAMP
for 24 h, and then treated with LPS or IFN-
, or their combination for 6 or 12 h (Fig. 2 A). Fig. 2, B and C, shows effects of various combinations of reagents on iNOS and
arginase II mRNAs. iNOS mRNA of ~4.5 kb was not evident in the untreated cells but was induced by LPS, and this induction was enhanced by IFN-
or Dex/cAMP, and
even more strongly by their combination. Dex/cAMP was
without effect. Arginase II mRNA of ~1.8 kb that was low
in untreated cells was induced by LPS or Dex/cAMP and
even more so by their combination. IFN-
strongly prevented the induction of arginase II by LPS, whereas it had
little effect on the induction by LPS plus Dex/cAMP. In other words, inhibition of LPS induction of arginase II
mRNA by IFN-
was alleviated by Dex/cAMP. cAMP
alone had some effect in such cases, whereas Dex alone
was ineffective (Fig. 2 D).
|
Fig. 2, E and F, shows immunoblot analysis of arginase
II protein in RAW cells treated with Dex/cAMP for 24 h
and then with LPS and/or IFN- for 12 h. Arginase II protein was induced by LPS and this induction was prevented
by IFN-
. It was also induced by Dex/cAMP, and LPS plus
Dex/cAMP appeared to have an additive effect. The induction of arginase II protein by LPS plus Dex/cAMP was
somewhat reduced by the further addition of IFN-
. The
results of arginase II protein were in accord with those of
arginase II mRNA (Fig. 2, B and C).
We then examined the effect of Dex and cAMP on LPS/
IFN--induced apoptosis of RAW cells (Fig. 2 G). When
cells were treated with LPS/IFN-
, iNOS but not arginase
II was induced. Under these conditions, apoptotic changes
were observed. These changes were effectively prevented
by Dex/cAMP; under these conditions both iNOS and arginase II were induced. Dex or cAMP alone was much less
effective than their combination in arginase II induction in
the presence of LPS/IFN-
(Fig. 2 D), and was not effective in preventing apoptosis.
Fig. 2 H shows results of agarose gel electrophoresis of
DNA. The formation of a DNA ladder, characteristic of
apoptotic cells, was observed when the cells were treated
with LPS/IFN-. This ladder formation was prevented by
Dex/cAMP. Dex or cAMP had little effect in preventing
ladder formation. All these results suggest strongly that
apoptosis is prevented by the induction of arginase II.
Transfection of Arginase Expression Plasmids Prevents iNOS-dependent Apoptosis of RAW Cells
To examine the effect of arginase on apoptosis even more
directly, transfection experiments were done. In a control
experiment, RAW cells were treated with LPS plus Dex/
cAMP to induce arginase II. After fixation, the cells were
immunostained with an antibody against arginase II (Fig.
3). Little immunoreactivity was observed in untreated
cells. On the other hand, when the cells were treated with
LPS plus Dex/cAMP, the cells became positive for arginase II immunoreactivity. Thread-like structures were
stained, results reflecting localization of arginase II in the
mitochondria (Gotoh et al., 1996). When the cells were
transiently transfected with the arginase II plasmid, some
cells that were apparently transfected with the plasmid were
strongly immunostained. Thread-like mitochondrial structures were visible in most of the positive cells, whereas whole cells were stained in some positive cells, probably
due to a high overexpression of the enzyme.
|
Fig. 4 shows the effect of arginase II expression on apoptosis of RAW cells. Apoptotic changes were observed by
the addition of LPS/IFN-. When the arginase II plasmid
was transfected, some cells were protected from apoptotic
change. Transfection of an expression plasmid for arginase
I, a cytosolic enzyme, was also effective in protecting cells
from LPS/IFN-
-dependent apoptosis. Transfection of the
insertless plasmid was without effect. These results support our hypothesis that arginase prevents apoptosis by
depleting intracellular arginine and thus decreasing production of NO. Both mitochondrial arginase II and cytosolic arginase I were effective.
|
To gain support for this hypothesis, we examined the effect of a NO donor SNAP on apoptosis of RAW cells. SNAP alone induced apoptosis of the cells. SNAP also canceled the antiapoptotic effects of Dex/cAMP or arginase II plasmid (data not shown). Therefore, the antiapoptotic effect of arginase relates to downregulation of NO production by the enzyme. In fact, when a high concentration of arginine (12 mM) was added to the culture medium, antiapoptotic effects of the arginase II plasmid were not observed, and all the cells underwent apoptosis (data not shown). 12 mM arginine alone induced no apoptotic change of the cells.
Arginase II Suppresses NO Production in RAW Cells
We next examined the effect of arginase II induction on
NO production in RAW cells (Fig. 5). NO production
measured by NO2 plus NO3 in the culture medium was not
detected in untreated cells. When the cells were treated
with LPS/IFN-, iNOS protein was induced and NO production was markedly increased. On the other hand, when Dex plus cAMP were included with LPS/IFN-
, iNOS protein was further induced, whereas arginase activity was
highly induced, and NO production was markedly decreased. These results suggest strongly that the induced arginase II competes with iNOS for arginine and suppresses
NO production.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Arginine is a common substrate for NOS and arginase. In
RAW cells, LPS/IFN- treatment induces iNOS and NO-mediated apoptosis. We obtained evidence that the induced arginase downregulates NO production by depleting arginine and hence preventing apoptosis. First, when
arginase II was induced by Dex/cAMP in activated cells, iNOS induction was not suppressed, but apoptosis was
prevented. Second, when the expression plasmid for arginase I or II was transiently transfected, some cells were
prevented from apoptosis. Third, a NO donor or a high
concentration of arginine canceled out this antiapoptotic
effect of arginase. Fourth, NO production was suppressed under conditions where the iNOS expression remained
high and arginase II was induced.
In cases of septic shock, iNOS is strongly induced and a
large amount of NO is produced. This high-output production of NO is thought to lead to various symptoms, especially hypotension (Moncada and Higgs, 1993). Glucocorticoids and epinephrine are prescribed in cases of shock
state. There are reports that glucocorticoids inhibit NF-
B
activity through the induction of I
B synthesis (Auphan
et al., 1995
; Scheinman et al., 1995
) and suppress expression of inflammatory genes, including the iNOS gene. Our
present results suggest that the combination of Dex, a synthetic glucocorticoid, and cAMP, a second messenger of
epinephrine, may also contribute to the antishock effect by
inducing arginase II and downregulating NO production.
If such is the case, arginase would be a good target for
therapy of septic shock and other conditions due to the
overexpression of NO. NOS inhibitors usually inhibit all
types of NOS and inhibition of constitutive types of NOS
may cause side effects. On the other hand, the demand of
iNOS for its substrate arginine is much higher than those
of constitutive NOSs because of its very high activity. The
induction of arginase may lead to selective inhibition of the high output NO production by iNOS.
We reported that iNOS and arginase I, not arginase II,
are coinduced by LPS in cultured rat peritoneal macrophages and in the lung and spleen in vivo (Sonoki et al.,
1997). The induction of arginase I is slower than that of
iNOS. Based on these findings, we suggested that iNOS is
first induced, NO is produced, and then arginase is induced and the sustained overproduction of NO that is
toxic to surrounding cells is prevented. In rat aortic endothelial cells, both constitutive and LPS-inducible arginase
activity were reported to be present (Buga et al., 1996
).
The constitutive presence of arginase I and induction of
arginase II by LPS were evident, as determined using
immunoprecipitation experiments. iNOS is known to be
highly induced in rat hepatocytes by the combination of tumor necrosis factor, IL-1, IFN-
, and LPS (Geller et al.,
1993
). Treatment of rats with glucocorticoids and cAMP
induces arginase I in hepatocytes (Morris et al., 1987
). It
remains to be seen whether expression of arginase I is affected by treatment with LPS in combination with glucocorticoids and cAMP.
Induction of arginase I and II differs between rats and
mice. As reported previously (Sonoki et al., 1997) and as
mentioned above, only arginase I is induced by LPS in rat
peritoneal macrophages and in the lung and spleen in vivo.
On the other hand, only arginase II is induced in mouse
macrophage-like RAW cells (Wang et al., 1995
; Gotoh et al.,
1996
). Thus, there appears to be a differential regulation
of expression of these two isoforms in various cell types in
various species. Despite this, our results show both forms
are effective in preventing NO-mediated apoptosis.
![]() |
Footnotes |
---|
Received for publication 23 March 1998 and in revised form 23 December 1998.
Address correspondence to Dr. Masataka Mori, Department of Molecular
Genetics, Kumamoto University School of Medicine, Kuhonji 4-24-1, Kumamoto 862-0976, Japan. Tel.: 81-96-373-5140. Fax: 81-96-373-5145. E-mail: masa{at}gpo.kumamoto-u.ac.jp
We thank M. Yano for technical advice and other colleagues for suggestions and discussion. We also thank M. Ohara for comments on the manuscript.
This work was supported in part by Grants-in-Aid (08457040 to M. Mori and 09770099 to T. Gotoh) from the Ministry of Education, Science, Sports, and Culture of Japan, and a grant (to M. Mori) from Taisho Pharmaceutical Company.
![]() |
Abbreviations used in this paper |
---|
carboxy-PTIO, 2-(4-carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide;
Dex, dexamethasone;
IFN-, interferon-
;
iNOS, inducible NO synthase;
LPS, lipopolysaccharide;
NO, nitric oxide;
NOS, NO synthase;
SNAP, S-nitroso-N-acetyl-DL-penicillamine.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Akaike, T., M. Yoshida, Y. Miyamoto, K. Sato, M. Kohno, K. Sasamoto, K. Miyazaki, S. Ueda, and H. Maeda. 1993. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry. 32: 827-832 |
2. |
Albina, J.E.,
S. Cui,
R.B. Mateo, and
J.S. Reichner.
1993.
Nitric oxide-mediated
apoptosis in murine peritoneal macrophages.
J. Immunol.
150:
5080-5085
|
3. |
Auphan, N.,
J.A. DiDonato,
C. Rosette,
A. Helmberg, and
M. Karin.
1995.
Immunosuppression by glucocorticoids: inhibition of NF-![]() ![]() |
4. | Blanco, F.J., R.L. Ochs, H. Schwarz, and M. Lotz. 1995. Chondrocyte apoptosis induced by nitric oxide. Am. J. Pathol. 146: 75-85 [Abstract]. |
5. | Bonfoco, E., D. Krainc, M. Ankarcrona, P. Nicotera, and S.A. Lipton. 1995. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc. Natl. Acad. Sci. USA. 92: 7162-7166 [Abstract]. |
6. |
Buga, G.M.,
R. Singh,
S. Pervin,
N.E. Rogers,
D.A. Schmitz,
C.P. Jenkinson,
S.D. Cederbaum, and
L.J. Ignarro.
1996.
Arginase activity in endothelial
cells: inhibition by NG-hydroxy-L-arginine during high-output NO production.
Am. J. Physiol.
271:
H1988-H1998
|
7. | Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159 |
8. |
Christopherson, K.S., and
D.S. Bredt.
1997.
Nitric oxide in excitable tissues:
physiological roles and disease.
J. Clin. Invest.
100:
2424-2429
|
9. |
Corbett, J.A., and
M.L. McDaniel.
1992.
Does nitric oxide mediate autoimmune destruction of ![]() |
10. | Dawson, V.L., V.M. Kizushi, P.L. Huang, S.H. Snyder, and T.M. Dawson. 1996. Resistance to neurotoxicity in cortical cultures from neuronal nitric oxide synthase-deficient mice. J. Neurosci. 16: 2479-2487 [Abstract]. |
11. | Dimmeler, S., and A.M. Zeiher. 1997. Nitric oxide and apoptosis: another paradigm for the double-edged role of nitric oxide. Nitric Oxide. 1: 275-281 . |
12. | Enari, M., H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu, and S. Nagata. 1998. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391: 43-50 |
13. | Farrell, A.J., D.R. Blake, R.M. Palmer, and S. Moncada. 1992. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis. 51: 1219-1222 [Abstract]. |
14. | Fehsel, K., A. Jalowy, S. Qi, V. Burkart, B. Hartmann, and H. Kolb. 1993. Islet cell DNA is a target of inflammatory attack by nitric oxide. Diabetes. 42: 496-500 [Abstract]. |
15. |
Gaido, M.L., and
J.A. Cidlowski.
1991.
Identification, purification, and characterization of a calcium-dependent endonuclease (NUC18) from apoptotic
rat thymocytes. NUC18 is not histone H2B.
J. Biol. Chem.
266:
18580-18585
|
16. | Geller, D.A., A.K. Nussler, M. Di Silvio, C.J. Lowenstein, R.A. Shapiro, S.C. Wang, R.L. Simmons, and T.R. Billiar. 1993. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc. Natl. Acad. Sci. USA. 90: 522-526 [Abstract]. |
17. | Gotoh, T., T. Sonoki, A. Nagasaki, K. Terada, M. Takiguchi, and M. Mori. 1996. Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett. 395: 119-122 |
18. | Gotoh, T., M. Araki, and M. Mori. 1997. Chromosomal localization of the human arginase II gene and tissue distribution of its mRNA. Biochem. Biophys. Res. Commun. 233: 487-491 |
19. | Grody, W.W., C. Argyle, R.M. Kern, G.J. Dizikes, E.B. Spector, A.D. Strickland, D. Klein, and S.D. Cederbaum. 1989. Differential expression of the two human arginase genes in hyperargininemia. Enzymatic, pathologic, and molecular analysis. J. Clin. Invest. 83: 602-609 |
20. | Hale, A.J., C.A. Smith, L.C. Sutherland, V.E. Stoneman, V.L. Longthorne, A.C. Culhane, and G.T. Williams. 1996. Apoptosis: molecular regulation of cell death. Eur. J. Biochem. 236: 1-26 [Abstract]. |
21. |
Harrison, D.G..
1997.
Cellular and molecular mechanisms of endothelial cell
dysfunction.
J. Clin. Invest.
100:
2153-2157
|
22. |
Hattori, Y.,
E.B. Campbell, and
S.S. Gross.
1994.
Argininosuccinate synthetase
mRNA and activity are induced by immunostimulants in vascular smooth
muscle. Role in the regeneration or arginine for nitric oxide synthesis.
J.
Biol. Chem.
269:
9405-9408
|
23. | Hecker, M., W.C. Sessa, H.J. Harris, E.E Anggard, and J.R. Vane. 1990. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc. Natl. Acad. Sci. USA. 87: 8612-8616 [Abstract]. |
24. | Hibbs, J.J., R.R. Taintor, Z. Vavrin, and E.M. Rachlin. 1988. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem. Biophys. Res. Commun. 157: 87-94 |
25. | Juedes, M.J., and G.N. Wogan. 1996. Peroxynitrite-induced mutation spectra of pSP189 following replication in bacteria and in human cells. Mutat. Res. 349: 51-61 |
26. |
Kaneto, H.,
J. Fujii,
H.G. Seo,
K. Suzuki,
T. Matsuoka,
M. Nakamura,
H. Tatsumi,
Y. Yamasaki,
T. Kamada, and
N. Taniguchi.
1995.
Apoptotic cell
death triggered by nitric oxide in pancreatic ![]() |
27. |
Kawamoto, S.,
Y. Amaya,
K. Murakami,
F. Tokunaga,
S. Iwanaga,
K. Kobayashi,
T. Saheki,
S. Kimura, and
M. Mori.
1987.
Complete nucleotide sequence of cDNA and deduced amino acid sequence of rat liver arginase.
J.
Biol. Chem.
262:
6280-6283
|
28. | Kerr, J.F.R.. 1995. Neglected opportunities in apoptosis research. Trends Cell Biol. 5: 55-57 . |
29. |
Kim, Y.M.,
H.A. Bergonia,
C. Muller,
B.R. Pitt,
W.D. Watkins, and
J.J. Lancaster.
1995.
Loss and degradation of enzyme-bound heme induced by cellular nitric oxide synthesis.
J. Biol. Chem.
270:
5710-5713
|
30. | Kröncke, K.D., K. Fehsel, and V. Kolb-Bachofen. 1997. Nitric oxide: Cytotoxicity versus cytoprotection-how, why, when, and where? Nitric Oxide. 1: 107-120 . |
31. | Kwon, N.S., D.J. Stuehr, and C.F. Nathan. 1991. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J. Exp. Med. 174: 761-767 [Abstract]. |
32. | Lepoivre, M., F. Fieschi, J. Coves, L. Thelander, and M. Fontecave. 1991. Inactivation of ribonucleotide reductase by nitric oxide. Biochem. Biophys. Res. Commun. 179: 442-448 |
33. | Mayer, B., and B. Hemmens. 1997. Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem. Sci. 22: 477-481 |
34. |
Messmer, U.K.,
U.K. Reed, and
B. Brune.
1996.
Bcl-2 protects macrophages
from nitric oxide-induced apoptosis.
J. Biol. Chem.
271:
20192-20197
|
35. |
Miura, M.,
H. Zhu,
R. Rotello,
E.A. Hartwieg, and
J. Yuan.
1993.
Induction of
apoptosis in fibroblasts by IL-1![]() |
36. |
Molina y Vedia, L.,
B. McDonald,
B. Reep,
B. Brüne,
M. Di Silvio,
T.R. Billiar, and
E.G. Lapetina.
1992.
Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases
endogenous ADP-ribosylation.
J. Biol. Chem.
267:
24929-24932
|
37. |
Moncada, S., and
A. Higgs.
1993.
The L-arginine-nitric oxide pathway.
N. Engl.
J. Med.
329:
2002-2012
|
38. | Morris, S.J., C.L. Moncman, K.D. Rand, G.J. Dizikes, S.D. Cederbaum, and W.E. O'Brien. 1987. Regulation of mRNA levels for five urea cycle enzymes in rat liver by diet, cyclic AMP, and glucocorticoids. Arch. Biochem. Biophys. 256: 343-353 |
39. | Morris, S.J., D. Bhamidipati, and D. Kepka-Lenhart. 1997. Human type II arginase: sequence analysis and tissue-specific expression. Gene. 193: 157-161 |
40. |
Nagasaki, A.,
T. Gotoh,
M. Takeya,
Y. Yu,
M. Takiguchi,
H. Matsuzaki,
K. Takatsuki, and
M. Mori.
1996.
Coinduction of nitric oxide synthase, argininosuccinate synthetase, and argininosuccinate lyase in lipopolysaccharide-treated rats. RNA blot, immunoblot, and immunohistochemical analyses.
J.
Biol. Chem.
271:
2658-2662
|
41. |
Nathan, C..
1997.
Inducible nitric oxide synthase: what difference does it make?
J. Clin. Invest.
100:
2417-2423
|
42. | Nguyen, T., D. Brunson, C.L. Crespi, B.W. Penman, J.S. Wishnok, and S.R. Tannenbaum. 1992. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc. Natl. Acad. Sci. USA. 89: 3030-3034 [Abstract]. |
43. | Nicholson, D.W., A. Ali, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, Y.A. Lazebnik, et al . 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376: 37-43 |
44. | Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108: 193-199 |
45. |
Nussler, A.K.,
T.R. Billiar,
Z.Z. Liu, and
S.J. Morris.
1994.
Coinduction of nitric
oxide synthase and argininosuccinate synthetase in a murine macrophage
cell line. Implications for regulation of nitric oxide production.
J. Biol.
Chem.
269:
1257-1261
|
46. | Peitsch, M.C., B. Polzar, H. Stephan, T. Crompton, H.R. MacDonald, H.G. Mannherz, and J. Tschopp. 1993. Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). EMBO (Eur. Mol. Biol. Organ.) J. 12: 371-377 [Abstract]. |
47. | Routledge, M.N., F.J. Mirsky, D.A. Wink, L.K. Keefer, and A. Dipple. 1994. Nitrite-induced mutations in a forward mutation assay: influence of nitrite concentration and pH. Mutat. Res. 322: 341-346 |
48. | Sarih, M., V. Souvannavong, and A. Adam. 1993. Nitric oxide synthase induces macrophage death by apoptosis. Biochem. Biophys. Res. Commun. 191: 503-508 |
49. |
Scheinman, R.I.,
P.C. Cogswell,
A.K. Lofquist, and
A.J. Baldwin.
1995.
Role of
transcriptional activation of I![]() ![]() |
50. |
Schimke, R.T..
1962.
Adaptive characteristics of urea cycle enzymes in the rat.
J.
Biol. Chem.
237:
459-468
|
51. | Shiokawa, D., H. Ohyama, T. Yamada, K. Takahashi, and S. Tanuma. 1994. Identification of an endonuclease responsible for apoptosis in rat thymocytes. Eur. J. Biochem. 226: 23-30 [Abstract]. |
52. |
Sonoki, T.,
A. Nagasaki,
T. Gotoh,
M. Takiguchi,
M. Takeya,
H. Matsuzaki, and
M. Mori.
1997.
Coinduction of nitric-oxide synthase and arginase I in
cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide.
J. Biol. Chem.
272:
3689-3693
|
53. | Stuehr, D.J., and M.A. Marletta. 1985. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc. Natl. Acad. Sci. USA. 82: 7738-7742 [Abstract]. |
54. | Vockley, J.G., C.P. Jenkinson, H. Shukla, R.M. Kern, W.W. Grody, and S.D. Cederbaum. 1996. Cloning and characterization of the human type II arginase gene. Genomics. 38: 118-123 |
55. | Wang, W.W., C.P. Jenkinson, J.M. Griscavage, R.M. Kern, N.S. Arabolos, R.E. Byrns, S.D. Cederbaum, and L.J. Ignarro. 1995. Co-induction of arginase and nitric oxide synthase in murine macrophages activated by lipopolysaccharide. Biochem. Biophys. Res. Commun. 210: 1009-1016 |